- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
- Others
Central Retinal Vein Occlusion Market was valued at USD 3.4 billion in 2023 and is poised to grow at a CAGR of 6.2% over 2024-2030. Central retinal vein occlusion (CRVO) is a condition in which the main vein that drains blood from the retina closes off partially or completely at or proximal to the lamina cribrosa of the optic nerve, where the central vein exists in the eye, causing blurred vision, and other eye problems. Based on the treatment type, Anti–vascular endothelial growth factor is anticipated to dominate the central retinal vein occlusion market share over the forecast period. According to a research report, globally, an estimated 2.5 million adults are affected by central retinal vein occlusion. The rise of ophthalmic disease with the increase in the elderly population will act as the central retinal vein occlusion market growth driver, whereas the high cost of treatment and side effects would be the restraining factor for the market. Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are opportunities for the expansion of the market.
Central Retinal Vein Occlusion Market Key Developments:
- In Feb 2023, Kodiak Sciences completed a phase-III BEACON trial in retinal vein occlusion in the USA, Czech Republic, France, Hungary, Israel, Italy, Latvia, Poland, and Others for KSI-301, an intravitreal injection.
Central Retinal Vein Occlusion Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.2%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Central Retinal Vein Occlusion Market Dynamics
The increasing prevalence of diabetes and atherosclerosis and rising cases of patients with myeloma, lymphoma, and glaucoma are the major factors accelerating the growth of the central retinal vein occlusion market. Furthermore, there are emerging therapies including ONS-5010, KSI-301, Vabysmo, and others for retinal vein occlusion with the potential to create a positive shift in the market. Thus, the increased awareness, research, and development for eye disorders will lead to market growth within the forecast period.
North-America Got Significant Share
Central Retinal Vein Occlusion Market Regional Analysis
According to the data collected from international epidemiological studies, the prevalence rate for CRVO ranges between 0.3% and 2.1% across the world. The North America Central Retinal Vein Occlusion market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and the rising prevalence of diabetic population resulting into increased incidences of retinal disorders in this region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The central retinal vein occlusion market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Central Retinal Vein Occlusion Market Segmentation
By Treatment
By Disease Type
- Fabry Disease
- Tay-Sachs Disease
- Gaucher’s Disease
- Pompe’s Disease
- Others
By End User
- Hospitals
- Clinics
- Homecare
- Others
Frequently Asked Questions
The Central Retinal Vein Occlusion market was valued at USD 3.4 million in 2022 and is expected to grow at a 6.2% CAGR over the forecast period 2023 – 2029.
Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are the key opportunities for the Central Retinal Vein Occlusion market.
The rise of ophthalmic disease with the increase in elderly population are the growth drivers in the Central Retinal Vein Occlusion market.
Allergan, Bayer AG, IRIDEX Corporation, Lumenis, Novartis AG, NIDEK CO., LTD., Roche Ltd., Regeneron Pharmaceuticals, Inc., Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, and Amgen Inc. are a few companies operating in the Central Retinal Vein Occlusion market.
| 1.Executive Summary |
| 2.Global Central Retinal Vein Occlusion Market Introduction |
| 2.1.Global Central Retinal Vein Occlusion Market - Taxonomy |
| 2.2.Global Central Retinal Vein Occlusion Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2.Disease Type |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Central Retinal Vein Occlusion Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Central Retinal Vein Occlusion Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Central Retinal Vein Occlusion Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Enzyme Replacement Therapy |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Stem Cell Therapy |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Substrate Reduction Therapy |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Central Retinal Vein Occlusion Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Fabry Disease |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Tay-Sachs Disease |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Gaucher’s Disease |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Pompe’s Disease |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Central Retinal Vein Occlusion Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Central Retinal Vein Occlusion Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Enzyme Replacement Therapy |
| 9.1.2.Stem Cell Therapy |
| 9.1.3.Substrate Reduction Therapy |
| 9.1.4.Others |
| 9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Fabry Disease |
| 9.2.2.Tay-Sachs Disease |
| 9.2.3.Gaucher’s Disease |
| 9.2.4.Pompe’s Disease |
| 9.2.5.Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Clinics |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Enzyme Replacement Therapy |
| 10.1.2.Stem Cell Therapy |
| 10.1.3.Substrate Reduction Therapy |
| 10.1.4.Others |
| 10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Fabry Disease |
| 10.2.2.Tay-Sachs Disease |
| 10.2.3.Gaucher’s Disease |
| 10.2.4.Pompe’s Disease |
| 10.2.5.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Clinics |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Enzyme Replacement Therapy |
| 11.1.2.Stem Cell Therapy |
| 11.1.3.Substrate Reduction Therapy |
| 11.1.4.Others |
| 11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Fabry Disease |
| 11.2.2.Tay-Sachs Disease |
| 11.2.3.Gaucher’s Disease |
| 11.2.4.Pompe’s Disease |
| 11.2.5.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Clinics |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Enzyme Replacement Therapy |
| 12.1.2.Stem Cell Therapy |
| 12.1.3.Substrate Reduction Therapy |
| 12.1.4.Others |
| 12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Fabry Disease |
| 12.2.2.Tay-Sachs Disease |
| 12.2.3.Gaucher’s Disease |
| 12.2.4.Pompe’s Disease |
| 12.2.5.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Clinics |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Central Retinal Vein Occlusion Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Enzyme Replacement Therapy |
| 13.1.2.Stem Cell Therapy |
| 13.1.3.Substrate Reduction Therapy |
| 13.1.4.Others |
| 13.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Fabry Disease |
| 13.2.2.Tay-Sachs Disease |
| 13.2.3.Gaucher’s Disease |
| 13.2.4.Pompe’s Disease |
| 13.2.5.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Clinics |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Allergan |
| 14.2.2.Bayer AG |
| 14.2.3.IRIDEX Corporation |
| 14.2.4.Lumenis |
| 14.2.5.Novartis AG |
| 14.2.6.NIDEK CO., LTD. |
| 14.2.7.Roche Ltd. |
| 14.2.8.Regeneron Pharmaceuticals, Inc. |
| 14.2.9.Topcon Corporation |
| 14.2.10.Merck & Co., Inc. |
| 14.2.11.Carl Zeiss AG |
| 14.2.12.Alimera Sciences |
| 14.2.13.Annexin Pharmaceuticals |
| 14.2.14.Amgen Inc. |
| 14.2.15.Bosch Healthcare Solutions GmbH |
| 14.2.16.Baxter |
| 14.2.17.Novartis AG |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Allergan
- Bayer AG
- IRIDEX Corporation
- Lumenis
- Novartis AG
- NIDEK CO., LTD.
- Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- Topcon Corporation
- Merck & Co., Inc.
- Carl Zeiss AG
- Alimera Sciences
- Annexin Pharmaceuticals
- Amgen Inc.
- Bosch Healthcare Solutions GmbH
- Baxter
- Novartis AG